Get all premium features to the best stock analysis tool

Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data

Combination of high quality, variable-rich, curated EHR data with genomics enhances understanding of the patient journey and aids in therapy development  SAN FRANCISCO, March 24, 2026 /PRNewswire/ -- Verana Health ®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of Verana's regulatory-grade, therapeutic-specific EHR curated datasets from leading medical societies and academic and community medical centers and Guardant's clinicogenomic testing data to accelerate the development of new therapies and enhance on-going patient care. Using the extensive datasets the collaboration provides, research scientists can more easily understand and further validate correlations between molecular biomarkers, treatment decisions and clinical outcomes.

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

PALO ALTO, Calif. & HONG KONG--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Shield™ multi-cancer detection (MCD) laboratory developed test (LDT) in multiple markets in Asia. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who a.

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of a new national survey conducted on its behalf by The Harris Poll with findings demonstrating that more than 9 out of 10 Americans ages 45 and over believe in ensuring broader coverage for blood-based colorectal cancer (CRC) screening, including new innovations like Shield™ by Guardant, a methylation partitioning cell-free DNA (mp-cfDNA) test and the first.

Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Shield™ by Guardant blood-based screening test is now widely accessible for physician order through the nationwide connectivity of Quest Diagnostics, equipping clinicians with access to blood-based screening innovation for colorectal cancer (CRC) through one of the largest diagnostic ecosystems in the United States. Shield is the first and only blood test to rec.